New analysis seeks to find mutations that predict response to Amgen's Vectibix in colorectal cancer
This article was originally published in Scrip
Executive Summary
In a new exploratory, retrospective biomarker analysis of a pivotal trial of Vectibix (panitumumab), Amgen has sought to identify which mutations beyond those in the KRAS proto-oncogene may predict resistance or response to the EGFR targeted drug when it is used to treat metastatic colorectal cancer (mCRC).